A Twelve Week Safety and Efficacy Study in Rosacea

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2014

Conditions
Papulopustular Rosacea
Interventions
DRUG

omiganan

DRUG

placebo

Trial Locations (17)

11790

Derm Research Center of NY Inc., Stoney Brook

14625

Rochester General Medical Group Center for Dermatology at Linden Oaks, Rochester

23507

Virginia Clinical Research Inc., Norfolk

27612

Wake Resarch, Raleigh

32204

North Florida Dermatology Associates, Jacksonville

33486

Skin Care Research, Inc, Boca Raton

34698

Dunedin Research Specialists, Dunedin

35209

Radiant Research Inc., Birmingham

37215

Tennessee Clinical Research Center, Nashville

37674

TriCities Skin and Cancer, Johnson City

46256

Dawes Fretzin Clinical Research Group, Indianapolis

48088

Grekin Skin Institute, Warren

78229

Progressive Clinical Research, PA, San Antonio

84117

Dermatology Research Center, Salt Lake City

90404

ATS Clinical Research, Santa Monica

97210

Oregon Dermatology and Research Center, Portland

06511

The Savin Center, PC, New Haven

All Listed Sponsors
lead

Maruho Co., Ltd.

INDUSTRY

NCT01784133 - A Twelve Week Safety and Efficacy Study in Rosacea | Biotech Hunter | Biotech Hunter